SciSparc Ltd. (NASDAQ: SPRC) is back on traders’ radar after a frenetic week of news that spans quantum bio‑data analytics, medical endoscopy devices and ongoing restructuring of its biotech portfolio.
As of Friday, December 5, 2025, SciSparc shares are trading around $1.79–$1.80, after an early pre‑market jump of about 19% to $2.10, on volume that has already surged well above normal levels. [1]
Despite today’s bounce, the stock remains down roughly 60–75% over the past year and more than 95% below its 52‑week high of $37.59, leaving the company with a micro‑cap market value of roughly $5.6–$5.9 million. [2]
Below is a breakdown of what is driving SciSparc now, how the latest deals fit into its strategy, and what various models and services are saying about the stock’s outlook.
Current SPRC Stock Performance on December 5, 2025
Real‑time data shows SciSparc trading near $1.79 on the Nasdaq on Friday afternoon, with an intraday range stretching from about $1.75 up to intraday highs above $2.60 and volume exceeding 11 million shares — several times its recent daily average. [3]
End‑of‑day historical data for December 5 currently records a close at $1.80 on volume of 10.99 million shares, up from 258,000 shares the previous day, highlighting just how abruptly SPRC can become a momentum trader favorite. [4]
Across data providers:
- 52‑week range: about $1.60 (low) to $37.59 (high). [5]
- 1‑year performance: roughly ‑60% to ‑76%, depending on methodology and exact look‑back date. [6]
- 3‑year performance: approximately ‑99.7%, reflecting years of dilution and price resets. [7]
- Market cap: around $5.6–$5.9 million. [8]
Retail‑oriented outlet Sete News, in a piece published today titled “Ready to Jump After Recent Trade: SciSparc Ltd (SPRC)”, notes that SPRC has dropped over 20% in the past week, more than 40% in a month, and over 70% in a year, while trading within that $1.60–$37.59 band and showing a beta near 1.25. [9]
In short: SPRC is tiny, extremely volatile, and highly sensitive to news.
December Catalysts: Quantum Bio‑Data Deal via NeuroThera
The first major December catalyst hit on December 2, 2025.
SciSparc announced that its majority‑owned subsidiary NeuroThera Labs Inc. (TSXV: NTLX), in which SciSparc controls about 75%, signed a non‑binding term sheet to acquire a 55% equity stake in an Israeli quantum computing bio‑data analysis company. [10]
Key points from the deal outline:
- NeuroThera would issue new common shares equal to 40% of its share capital (non‑diluted) to the target company’s selling shareholders in exchange for the 55% stake. [11]
- The target focuses on quantum‑enabled clinical analytics, aiming to integrate quantum computing with bioinformatics and clinical trial data to speed up drug development and improve insight quality. [12]
- The agreement is non‑binding and remains subject to due diligence, definitive documentation and corporate/regulatory approvals. [13]
SciSparc itself doesn’t directly buy the quantum company, but because it controls NeuroThera, the transaction would deepen SciSparc’s exposure to quantum‑powered analytics in clinical development — something the company has been leaning toward since announcing quantum‑enabled 3D protein modeling initiatives earlier this year. [14]
Market reaction has been broadly positive but choppy: news aggregators and analytics platforms group the December 2 announcement among the top recent positive catalysts for SPRC, and today’s elevated volume suggests traders are still positioning around this theme. [15]
GERD Device Pivot: MUSE™ and the Endoscopy IP Portfolio
The second big December storyline is SciSparc’s attempt to step outside pure pharmaceuticals into the GERD (gastroesophageal reflux disease) device market.
On November 26 and December 1, 2025, the company announced and then reiterated a binding term sheet to acquire a portfolio of patents, trademarks and related know‑how for medical endoscopy systems and cameras, including the single‑use MUSE™ transoral fundoplication system, from Xylo Technologies Ltd. [16]
Highlights:
- The MUSE™ system is designed for minimally invasive treatment of GERD via transoral fundoplication. [17]
- Xylo previously licensed the technology in Greater China to a Shanghai‑based partner in 2019, reportedly receiving $3 million upfront, giving SciSparc a real‑world commercialization blueprint to point to. [18]
- At closing, SciSparc plans to issue ordinary shares representing 19.99% of its then‑outstanding share capital to Xylo (or, at its discretion, issue pre‑funded warrants instead of some or all of those shares). [19]
The company is clearly pitching this as an entry into a multi‑billion‑dollar device market: according to a MarkNtel Advisors report cited in the press releases, the global GERD device market was valued at around $2.5 billion in 2024 and is projected to grow to $3.03 billion by 2030 at a 3.24% CAGR. [20]
For shareholders, the strategic trade‑off is straightforward:
- Upside: A proven product (MUSE™), a growing niche device market, and the potential for royalty‑ or distribution‑based revenues instead of relying solely on binary biotech trial outcomes.
- Downside: Issuing nearly 20% of the company’s equity (or equivalent pre‑funded warrants) is meaningfully dilutive for existing holders, and the deal still hinges on definitive agreements and regulatory approvals. [21]
A Reshaped Corporate Structure: NeuroThera, MitoCareX and N2OFF
The December moves make more sense in the context of SciSparc’s busy autumn:
- NeuroThera Labs acquisition (October 24, 2025)
SciSparc closed a transaction with Miza III Ventures Inc., now renamed NeuroThera Labs Inc. (TSXV: NTLX), transferring its advanced clinical‑stage pharmaceutical portfolio and its majority stake in SciSparc Nutraceuticals into NeuroThera. In return, SciSparc received 63.3 million NeuroThera shares, 4 million warrants, and up to 48 million contingent rights, giving it a ~75% controlling stake, potentially rising to about 84% if warrants and milestone rights are fully exercised. [22] - Sale of MitoCareX to N2OFF (October 23, 2025)
One day earlier, SciSparc completed the sale of its majority‑owned oncology subsidiary MitoCareX Bio Ltd. to N2OFF Inc. (Nasdaq: NITO) for $700,000 in cash plus N2OFF shares corresponding to 40% of N2OFF’s fully diluted capital, along with milestone‑based stock rights and a share in future financing proceeds (capped at $1.6 million). [23]
These transactions effectively:
- Move SciSparc’s core cannabinoid CNS drug assets into NeuroThera, a separate public vehicle it controls.
- Convert MitoCareX into an indirect exposure via N2OFF shares and milestones rather than a majority‑owned subsidiary.
- Position SciSparc to layer quantum computing, endoscopy IP and cannabinoid pipelines under a more complex but potentially more flexible corporate umbrella. [24]
Core Pipeline and Psychedelic/Cannabinoid Collaboration
Underneath the corporate engineering, SciSparc remains, at its core, a clinical‑stage CNS and rare‑disease drug developer:
- SCI‑110 – a THC/CBD‑based candidate targeting Tourette syndrome and Alzheimer’s disease agitation, currently progressing through Phase IIb clinical programs. [25]
- SCI‑210 – a cannabidiol‑based formulation for autism spectrum disorder (ASD) and status epilepticus (severe seizures), with ongoing clinical trials in pediatric populations. [26]
- Through its subsidiaries, SciSparc also maintains a hemp seed oil‑based nutraceutical business selling products via Amazon’s marketplace. [27]
Alongside this, SciSparc has an extensive patent and co‑development collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) around psychedelic‑inspired combination therapies:
- On October 20, 2025, SciSparc and Clearmind announced publication of a U.S. patent application covering a combination of MEAI (5‑methoxy‑2‑aminoindane) with N‑acylethanolamines such as PEA for a range of binge‑behavior disorders, including alcohol abuse, eating disorders and substance addiction. [28]
- StockTitan’s analysis notes that the patent news drove a 38%+ single‑day move in SPRC, underlining how tightly the stock trades around headline risk. [29]
Add in the September launch of a quantum‑powered 3D protein modeling initiative aimed at speeding AI‑driven drug discovery, and SciSparc’s story today is less “one small cannabinoid biotech” and more a patchwork of early‑stage platforms: psychedelics, quantum analytics, endoscopy devices and CNS drug candidates. [30]
Reverse Split, Dilution and Balance Sheet Pressures
Investors following SPRC also have to grapple with a substantial capital‑structure overhang.
On June 24, 2025, SciSparc implemented a 1‑for‑21 reverse share split, reducing its outstanding ordinary shares from roughly 11.2 million to about 0.53 million (before subsequent issuances), in order to stay compliant with Nasdaq’s minimum bid requirements. [31]
Since then:
- Sites like IndMoney and StockTitan highlight a 3‑year return near –99.7% and one‑year performance around –60–76%, typical of a micro‑cap reliant on repeated equity financings. [32]
- Simply Wall St flags that SciSparc fails all six of its “future growth” checks due to a lack of analyst coverage and notes risk items such as negative shareholders’ equity and a recent follow‑on equity offering of around $2.26 million. [33]
In other words, the company continues to use the equity market as its primary source of capital, and new deals — whether endoscopy IP or quantum analytics — are at least partly funded in shares or warrants. Investors attracted by the story need to be comfortable with ongoing dilution risk.
Technical Picture: Oversold, High‑Volatility Micro‑Cap
Technical and quantitative services give a broadly bearish but highly volatile picture for SPRC as of December 5, 2025:
- CoinCodex reports:
- Current price used in its model: $1.70.
- 5‑day prediction: ~$1.80.
- 1‑month prediction: ~$1.79.
- Volatility:22.54% over the last 30 days.
- “Green days”: 14 out of 30 (47%).
- 50‑day SMA: ~$3.45 vs current price around $1.70.
- 14‑day RSI: about 23.8, which falls into “oversold” territory. [34]
- StockInvest.us notes that on Thursday, December 4, SciSparc gained 3.51%, moving from $1.71 to $1.77, yet is still down about 28% over the last 10 trading days, with daily swings near 12% and rising volume — a classic recipe for day‑trader volatility. [35]
- Intellectia.ai’s moving‑average dashboard labels SciSparc’s trend as bearish, with its short‑ and medium‑term moving averages (including the 20‑day vs 60‑day) signaling persistent downward pressure. [36]
- Benzinga quotes a Relative Strength Index (RSI) around 28, also consistent with an oversold reading, while listing short interest of about 1.8% of float and days to cover near 1.7, indicating only modest outright short positioning. [37]
Some services swing to the opposite extreme on upside projections:
- StockScan’s algorithmic forecast cites an average short‑term target of around $8.38 over the next 30 days and a 12‑month “price target” near $6.73, implying several hundred percent upside from current levels. The same page prominently includes a disclaimer that these outputs are not financial advice and are based on model assumptions, not analyst coverage. [38]
Such numbers highlight the speculative nature of SPRC: micro‑cap models often extrapolate from thin data and momentum, resulting in eye‑catching upside percentages that should be treated as scenario outputs rather than forecasts.
What Are Others Saying Today?
A range of daily commentary around December 5 gives a feel for how the market views SPRC right now:
- RTTNews lists SciSparc among the top pre‑market movers, noting the stock was up about 19% to $2.10 early in Friday’s session. [39]
- Sete News frames the stock as “ready to jump” after heavy recent losses, pointing to a small float (it cites ~1.62 million shares) and outlining negative performance metrics across one‑week, one‑month and six‑month windows. [40]
- Timothy Sykes / trader‑education blogs and prior articles on StockToTrade highlight how SciSparc has previously delivered single‑day moves of 30–50%+ around catalysts such as patent announcements, reverse‑merger headlines and quantum‑computing news. [41]
Data providers disagree on the exact number of shares outstanding and float — some list roughly 3.3 million shares, others closer to 1.6 million — but all agree it’s very small, which amplifies both upside spikes and downside collapses when volume comes in. [42]
Key Risks and Considerations for SciSparc Stock
For potential and current shareholders, several themes stand out:
- Execution risk on new deals
Both the quantum bio‑data acquisition (via NeuroThera) and the MUSE™ GERD/endoscopy IP deal are still contingent on definitive agreements, regulatory approvals and, in the case of NeuroThera, TSXV processes. There is no guarantee that either transaction will close on the proposed terms, or at all. [43] - Micro‑cap and dilution risk
SciSparc’s reverse split, history of equity offerings, negative shareholders’ equity and tiny market cap all point to ongoing reliance on capital markets. Each new financing, warrant issuance or share‑based acquisition potentially dilutes existing holders. [44] - Pipeline and regulatory risk
The company remains pre‑commercial: no approved drugs, no large recurring revenue stream from its core biotech business, and a heavy dependence on clinical trial outcomes and partnerships. New device and quantum initiatives add additional regulatory and operational complexity. - Volatility and trading behavior
With extreme day‑to‑day volatility, thin float and retail‑driven surges, SPRC behaves more like a trading vehicle than a stable long‑term investment at this stage. Algorithmic forecast sites disagree widely, and traditional Wall Street analyst coverage is effectively non‑existent. [45]
Bottom Line: A High‑Risk Story Stock Driven by Catalysts
As of December 5, 2025, SciSparc stock sits at the intersection of several speculative narratives:
- Quantum‑enhanced bio‑data analytics and 3D protein modeling through its majority‑owned NeuroThera Labs. [46]
- Entry into the GERD device and endoscopy market via the planned acquisition of Xylo’s MUSE™‑centric IP portfolio. [47]
- A legacy cannabinoid / psychedelic‑based CNS pipeline, including SCI‑110 and SCI‑210 and a broad Clearmind collaboration. [48]
- A heavily diluted, reverse‑split micro‑cap whose share price has collapsed over the long term but still occasionally delivers sharp news‑driven spikes. [49]
For short‑term traders, SPRC is likely to remain a high‑beta, catalyst‑sensitive ticker as the market digests the December deals and watches for concrete progress on quantum analytics, GERD device commercialization, and NeuroThera’s TSXV trajectory.
For longer‑term investors, SciSparc represents a very high‑risk, highly speculative bet on management’s ability to knit together quantum computing, medical devices and CNS drug development into a coherent, sustainable business — while navigating ongoing dilution and balance‑sheet constraints.
Nothing in this article is investment advice. Anyone considering SciSparc stock should perform their own due diligence, review the company’s SEC filings and risk factors, and consider consulting a licensed financial professional before making any trading or investment decisions.
References
1. stockanalysis.com, 2. www.indmoney.com, 3. stockanalysis.com, 4. stockanalysis.com, 5. www.benzinga.com, 6. www.indmoney.com, 7. www.indmoney.com, 8. www.stocktitan.net, 9. setenews.com, 10. www.globenewswire.com, 11. www.globenewswire.com, 12. www.globenewswire.com, 13. www.globenewswire.com, 14. stockstotrade.com, 15. www.stocktitan.net, 16. www.globenewswire.com, 17. www.globenewswire.com, 18. www.globenewswire.com, 19. www.globenewswire.com, 20. www.globenewswire.com, 21. www.globenewswire.com, 22. www.stocktitan.net, 23. www.stocktitan.net, 24. www.stocktitan.net, 25. www.globenewswire.com, 26. www.globenewswire.com, 27. www.globenewswire.com, 28. www.stocktitan.net, 29. www.stocktitan.net, 30. stockstotrade.com, 31. www.globenewswire.com, 32. www.indmoney.com, 33. simplywall.st, 34. coincodex.com, 35. stockinvest.us, 36. intellectia.ai, 37. www.benzinga.com, 38. stockscan.io, 39. www.rttnews.com, 40. setenews.com, 41. stockstotrade.com, 42. www.stocktitan.net, 43. www.globenewswire.com, 44. www.globenewswire.com, 45. coincodex.com, 46. www.globenewswire.com, 47. www.globenewswire.com, 48. www.globenewswire.com, 49. www.globenewswire.com
